ENJUVIA (estrogens, conjugated synthetic b) by Aspen Surgical is clinical pharmacology endogenous estrogens are largely responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Approved for the: treatment of moderate to severe vasomotor symptoms associated with menopause. First approved in 2004.
Drug data last refreshed 16h ago · AI intelligence enriched 6d ago
ENJUVIA is an oral tablet containing synthetic conjugated estrogens (estrone and equilin) approved for treating moderate to severe vasomotor symptoms associated with menopause. It works by binding to nuclear estrogen receptors in estrogen-responsive tissues and modulating pituitary gonadotropin secretion to reduce elevated LH and FSH levels in postmenopausal women. The formulation provides slow release over several hours for sustained pharmacokinetic exposure.
Product is approaching loss of exclusivity with moderate competitive pressure (30), signaling potential team restructuring and transition planning.
CLINICAL PHARMACOLOGY Endogenous estrogens are largely responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol is the principal…
Worked on ENJUVIA at Aspen Surgical? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
A Clinical Trial to Evaluate the Safety and Efficacy of Enjuvia 0.3 mg for the Treatment of Vulvovaginal Atrophy
ENJUVIA offers career opportunities primarily in commercial execution and market maintenance roles within a mature, declining product franchise. Working on this asset provides stable employment but limited growth trajectory, with emphasis on operational efficiency and customer relationship management rather than innovation or expansion.